7 January 2016 - AbbVie today announced that the U.S. FDA has accepted its supplemental New Drug Application and granted priority review for Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without ribavirin (RBV) in patients with genotype 1b chronic hepatitis C virus and compensated cirrhosis (Child-Pugh A).

For more details, go to: http://abbvie.mediaroom.com/2016-01-07-U-S-FDA-Grants-Priority-Review-to-AbbVie-for-Supplemental-New-Drug-Application-for-VIEKIRA-PAK-ombitasvir-paritaprevir-ritonavir-tablets-dasabuvir-tablets-without-Ribavirin-in-Genotype-1b-Chronic-Hepatitis-C-Virus-Patients-with-Compensated-Cirr